Social affairs correspondent Robert Booth tells Madeleine Finlay why a class of synthetic opioids called nitazenes, first developed in the 1950s, is leading to a worrying number of fatal overdoses in the UK. And she hears from toxicology and addiction specialist Dr Joseph D’Orazio about a tranquilliser called xylazine that has been showing up in alarming volumes in the US illegal drug supply and is now starting to appear in toxicology reports in the UK. Help support our independent journalism at theguardian.com/sciencepod
Wissenschaft & Technik
Science Weekly Folgen
Twice a week, the Guardian brings you the latest science and environment news
Folgen von Science Weekly
299 Folgen
-
Folge vom 20.02.2024Nitazenes and xylazine: what’s behind the rise of dangerous synthetic drugs?
-
Folge vom 15.02.2024What apes can tell us about the origins of teasingWe all know people who find it hilarious to prod and poke, pinch and tickle, all in the name of fun. But are humans the only ones who like to tease each other? Or are other animals in on the act? Ian Sample talks to Prof Erica Cartmill about her work on apes and teasing and asks, given how annoying teasing is, why do apes, and humans, do it?. Help support our independent journalism at theguardian.com/sciencepod
-
Folge vom 13.02.2024Retinol, acids and serums for kids? A dermatologist’s guide to age appropriate skincareLast month the British Association of Dermatologists warned that children as young as eight years old were using potentially damaging anti-ageing skin care products. Madeleine Finlay speaks to consultant dermatologist Dr Emma Wedgeworth about where this trend has come from, what damage these products might be causing to young skin and how we can all look after our skin without spending too much time and money. Help support our independent journalism at theguardian.com/sciencepod
-
Folge vom 08.02.2024Why are we still waiting for a male contraceptive pill?Despite research into a male contraceptive pill starting around the same time as its female counterpart, no product has ever made it to market. But that could soon change, with a new non-hormonal male pill entering human trials in the UK late last year. Ian Sample speaks to bioethicist Prof Lisa Campo-Engelstein of the University of Texas and Prof Chris Barratt from the University of Dundee about why male contraceptives have been so difficult to develop, and what kind of options are in the pipeline. Help support our independent journalism at theguardian.com/sciencepod